Mark Smith - Teladoc Independent Director

4LL Stock  EUR 9.11  0.39  4.11%   

Director

Dr. Mark Douglas Smith, M.D. is Independent Director of the Company. Dr. Smith is a professor of clinical medicine at the University of California at San Francisco as well as a visiting professor at the School of Public Health at the University of California at Berkeley. He is a boardcertified internist and maintains a clinical practice in HIV care at San Francisco General Hospital. A nationally recognized care delivery and health policy expert, Dr. Smith is current cochair of the Guiding Committee of the Health Care Payment Learning and Action Network, a publicprivate partnership launched by the U.S. Department of Health and Human Services. The group promotes the transition to valuebased payment to improve care quality while lowering costs. From 1996 to 2013, Dr. Smith served as the founding president and CEO of the California Health Care Foundation, an independently endowed philanthropy that works to improve healthcare access and quality for Californians. He helped build the foundation into a nationally recognized leader in delivery system innovation, public reporting of care quality, and applications of new technology in healthcare. Dr. Smith was formerly executive vice president of the Henry J. Kaiser Family Foundation. He was elected to the Institute of Medicine in 2001 and chaired its Committee on the Learning Healthcare System, which produced the landmark 2012 report, Best Care at Lower Cost. He serves on the boards of the Institute for Healthcare Improvement and the Commonwealth Fund and is on the editorial board of Health Affairs since 2018.
Age 67
Tenure 7 years
Phone203 635 2002
Webhttps://www.teladochealth.com
Smith received a bachelor degree in AfroAmerican studies from Harvard College, a medical doctorate from the University of North Carolina at Chapel Hill and a master degree in business, with a concentration in health care administration, from the Wharton School at the University of Pennsylvania. Our Board has concluded that Dr. Smith should serve as a director because of his broad experience in the healthcare industry.

Mark Smith Latest Insider Activity

Tracking and analyzing the buying and selling activities of Mark Smith against Teladoc stock is an integral part of due diligence when investing in Teladoc. Mark Smith insider activity provides valuable insight into whether Teladoc is net buyers or sellers over its current business cycle. Note, Teladoc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teladoc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Teladoc Management Efficiency

The company has return on total asset (ROA) of (0.0129) % which means that it has lost $0.0129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4885) %, meaning that it generated substantial loss on money invested by shareholders. Teladoc's management efficiency ratios could be used to measure how well Teladoc manages its routine affairs as well as how well it operates its assets and liabilities.
100%
Teladoc has accumulated 1.54 B in total debt with debt to equity ratio (D/E) of 0.09, which may suggest the company is not taking enough advantage from borrowing. Teladoc has a current ratio of 3.88, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Teladoc until it has trouble settling it off, either with new capital or with free cash flow. So, Teladoc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teladoc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teladoc to invest in growth at high rates of return. When we think about Teladoc's use of debt, we should always consider it together with cash and equity.
Debt68%Cash32%100%

Similar Executives

Found 1 records

DIRECTOR Age

James McKelveySquare Inc
58
Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. Teladoc Health, Inc. was Incorporated in 2002 and is headquartered in Purchase, New York. TELADOC HEALTH operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 3652 people. Teladoc (4LL) is traded on Frankfurt Exchange in Germany and employs 37 people.

Management Performance

Teladoc Leadership Team

Elected by the shareholders, the Teladoc's board of directors comprises two types of representatives: Teladoc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teladoc. The board's role is to monitor Teladoc's management team and ensure that shareholders' interests are well served. Teladoc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teladoc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Michael Goldstein, Independent Director
Mike Waters, Chief Officer
Andrew Turitz, Senior Vice President of Business Development
Catherine Jacobson, Independent Director
Sandra Fenwick, Director
Michelle Bucaria, Chief Human Resource Officer
Christopher Bischoff, Director
David Shedlarz, Independent Director
William Frist, Independent Director
Mala Murthy, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Controller
Mark Smith, Independent Director
David Snow, Independent Chairman of the Board
David Sides, Chief Operating Officer
Richard Napolitano, Chief VP
Thomas McKinley, Independent Director
Christopher Caridi, Senior Vice President Chief Accounting Officer, Controller
Karen Daniel, Director
Lewis Levy, Chief Medical Officer
Claus Jensen, Chief Officer
Adam Vandervoort, Chief Legal Officer and Secretary
Gabriel Cappucci, Senior Vice President Chief Accounting Officer, Controller
Kenneth Paulus, Independent Director
Stephanie Verstraete, Chief Marketing Officer
George Brooks, CoFounder
Hemant Taneja, Director
Glen Tullman, Director
Helen Darling, Independent Director
CPA CFA, VP Relations
Jason Gorevic, Chief Executive Officer, Director
Courtney McLeod, Director Communication

Teladoc Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teladoc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Additional Information and Resources on Investing in Teladoc Stock

When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Teladoc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Teladoc Stock please use our How to Invest in Teladoc guide.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Please note, there is a significant difference between Teladoc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teladoc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teladoc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…